Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
WHY IT'S IMPORTANT With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. KEY QUOTES "We've gotten to stage 1 and 2 on a global level, but in order to start recording sales at a quicker pace, we need to obtain a pipeline from outside. This acquisition is the first step in that direction," Ono Pharma CEO Gyo Sagara said at an online briefing. "After this first M&A, this does not mean that we will do a second or third, but we will always keep an eye on acquiring good compounds from the outside and will make sure to go in if we have a chance," he added. CONTEXT Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb. The drug expected to lose patent protection in major markets from 2028. The purchase includes Deciphera's oral drug Qinlock to treat a type of gastrointestinal cancer, which received th
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine ProAcquire Media Monitor
- Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual MeetingBusiness Wire
- AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s DiseaseBusiness Wire
- Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 5/9/24 - Form 6-K
- 5/9/24 - Form 6-K
- 5/9/24 - Form 6-K
- TAK's page on the SEC website